Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 169

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 169
---
The License Agreement may be terminated in its entirety or on a
Program-by-Program basis by us or WuXi Biologics, if the other party materially breaches the License Agreement, subject to specified notice and cure provisions, or if
the other party experiences certain events of financial distress. In addition, WuXi Biologics may terminate the License Agreement on a Program-by-Program basis
if Aadi does not meet certain development milestones. Further, we may terminate the License Agreement in entirety, or on a region-by-region, licensed product-by-licensed product, or Program-by-Program basis for convenience by giving a specified
number of days prior written notice to WuXi Biologics.

In the event the License Agreement is terminated following a first commercial sale of a licensed
product, we are entitled to sell our remaining inventory of such licensed product (for which regulatory approval has been received prior to such termination) for a certain period of time. At the expiration of such period of time, WuXi Biologics may
purchase any quantities of our remaining inventory at an agreed upon price.

Interests of Aadi’s Directors and Executive Officers in the PIPE Financing

Certain directors, affiliated funds of directors, and an executive officer of Aadi have interests in the PIPE
Financing that are different from, or in addition to, the interests of Aadi stockholders generally. Certain directors, affiliated funds of directors, and an executive officer of Aadi entered into the Subscription Agreement in connection with the
PIPE Financing, and committed to purchase an aggregate of 4,577,000 shares of common stock and 8,333,000 Pre-Funded Warrants. The PIPE Investors include entities that are related to Casey Castelein,
M.D., Anupam Dalal, M.D., Behzad Aghazadeh, Ph.D. and Baiteng Zhao, who serve on our board of directors, as well as an executive officer for the year ended December 31, 2024, Bryan Ball.

Additionally, it is expected that Dr. Lennon, Mr. Giacobello and Mr. Ball will continue to serve as executive officers of Aadi following the PIPE Financing
and that all members of Aadi’s board of directors will continue to

- 112 -

serve thereon following the PIPE Financing, and that such officers and directors will continue to receive cash and other compensation (including benefits) for such services under applicable plans
and arrangements which may be funded with proceeds from the PIPE Financing.

Aadi’s board of